[FPRX] Five Prime Therapeutics, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization: 1.25 B

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 51.31 Change: 0.98 (1.95%)
Ext. hours: Change: 0 (0%)

chart FPRX

Refresh chart

Strongest Trends Summary For FPRX

FPRX is in the medium-term down -69% below S&P in 1 year. In the long-term down -80% below S&P in 3 years and down -95% below S&P in 5 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of protein therapeutics that block cancer and inflammatory disease processes. The company?s product candidates include FP-1039/GSK3052230, a protein therapeutic, which is in Phase 1b clinical trials for trapping and neutralizing cancer-promoting fibroblast growth factors (FGFs) involved in cancer cell proliferation and new blood vessel formation; FPA008, a Phase 1 clinical trial stage antibody that inhibits colony stimulating factor-1 receptor; and FPA144 is an antibody for inhibiting FGF receptor 2b, as well as to treat patients with gastric cancer and potentially other solid tumors. It has collaboration and license agreements with GlaxoSmithKline LLC; Glaxo Group Limited; GSK-HGS; Pfizer Inc.; and UCB Pharma S.A. The company was founded in 2001 and is headquartered in South San Francisco, California.

Fundamental Ratios
Shares Outstanding28.2 M EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters -13.93% Sales Growth - Q/Q-7.71% P/E
P/E To EPS Growth P/S62.54 P/BV8.07 Price/Cash Per Share5.75
Price/Free Cash Flow91.69 ROA-17.73% ROE-25.73% ROI
Current Ratio11.41 Quick Ratio Long Term Debt/Equity Debt Ratio0.12
Gross Margin Operating Margin-200.57% Net Profit Margin-199.36% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities79.58 M Cash From Investing Activities-69.81 M Cash From Operating Activities-10.55 M Gross Profit
Net Profit-11.04 M Operating Profit-11.14 M Total Assets224.57 M Total Current Assets220.33 M
Total Current Liabilities19.31 M Total Debt Total Liabilities69.8 M Total Revenue4.29 M
Technical Data
High 52 week14.39 Low 52 week3.64 Last close4.13 Last change0.98%
RSI38.41 Average true range0.37 Beta1.41 Volume214.71 K
Simple moving average 20 days-4.79% Simple moving average 50 days-19.31% Simple moving average 200 days-51.47%
Performance Data
Performance Week11.92% Performance Month-27.03% Performance Quart-24.64% Performance Half-67.12%
Performance Year-68.47% Performance Year-to-date-55.59% Volatility daily5.62% Volatility weekly12.57%
Volatility monthly25.77% Volatility yearly89.27% Relative Volume286.4% Average Volume344.11 K
New High New Low

News

2020-05-15 09:37:01 | Is Five Prime Therapeutics FPRX Stock a Solid Choice Right Now?

2020-05-10 09:55:42 | Five Prime Therapeutics, Inc. NASDAQ:FPRX Just Reported And Analysts Have Been Cutting Their Estimates

2020-05-08 22:37:13 | Edited Transcript of FPRX earnings conference call or presentation 7-May-20 8:30pm GMT

2020-05-07 16:05:00 | Five Prime Therapeutics Reports First Quarter 2020 Results

2020-04-30 16:05:00 | Five Prime Therapeutics Announces Timing of Its First Quarter 2020 Results Conference Call

2020-04-22 16:05:00 | Five Prime Therapeutics Changes 2020 Annual Meeting to Virtual Format

2020-04-14 09:00:00 | Five Prime Therapeutics Appoints Tom Civik as Chief Executive Officer

2020-04-09 07:35:33 | Here's Why Five Prime Therapeutics NASDAQ:FPRX Must Use Its Cash Wisely

2020-03-18 23:04:59 | Edited Transcript of FPRX earnings conference call or presentation 27-Feb-20 9:30pm GMT

2020-03-13 09:25:00 | Five Prime Therapeutics Announces Publication of the Phase 1 Bemarituzumab Study in the Journal of Clinical Oncology

2020-02-27 17:45:10 | Five Prime Therapeutics FPRX Reports Q4 Loss, Misses Revenue Estimates

2020-02-25 16:22:00 | Five Prime Therapeutics to Present at Upcoming Healthcare Conference

2020-02-20 12:31:05 | Five Prime Therapeutics FPRX May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

2020-02-19 09:25:00 | Five Prime Therapeutics Licenses Antibodies to Seattle Genetics for Use in Novel Antibody Drug Conjugate ADC Programs

2020-02-18 09:25:00 | Five Prime Therapeutics Provides Update on Phase 2 Trial of Cabiralizumab Combined with Opdivo® in Pancreatic Cancer

2020-02-13 16:05:00 | Five Prime Therapeutics Announces Timing of Its Fourth Quarter and Full Year 2019 Results Conference Call

2020-01-10 09:28:03 | If You Had Bought Five Prime Therapeutics NASDAQ:FPRX Stock Three Years Ago, You'd Be Sitting On A 89% Loss, Today

2019-12-30 13:05:00 | Five Prime Therapeutics to Participate in the 38th Annual J.P. Morgan Healthcare Conference

2019-12-27 14:26:59 | Longtime biotech exec walks away from board to concentrate on startup

2019-12-26 16:05:00 | Five Prime Therapeutics Announces Resignation of Dr. Lewis T. "Rusty" Williams From Board of Directors

2019-12-20 13:54:34 | Head of big South San Francisco biotech thriving in first CEO role

2019-12-10 11:14:20 | Is Five Prime Therapeutics Inc FPRX A Good Stock To Buy ?

2019-11-12 14:22:56 | Edited Transcript of FPRX earnings conference call or presentation 6-Nov-19 9:30pm GMT

2019-11-09 07:00:00 | Five Prime Therapeutics Presents Initial Safety Data from the Phase 1 Trial of FPT155 at the Society for Immunotherapy of Cancer Annual Meeting

2019-11-08 13:02:40 | Insiders Roundup: Crocs, OPKO Health

2019-11-06 18:45:11 | Five Prime Therapeutics FPRX Reports Q3 Loss, Misses Revenue Estimates

2019-11-06 16:05:00 | Five Prime Therapeutics Reports Third Quarter 2019 Results

2019-10-30 10:33:02 | Five Prime Therapeutics FPRX May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

2019-10-24 16:01:00 | Five Prime Therapeutics to Announce Third Quarter 2019 Financial Results and Host Conference Call

2019-10-11 16:04:14 | Insiders Roundup: Facebook, American Defense Systems

2019-10-11 08:14:27 | The Daily Biotech Pulse: Therapix Extends Merger Deadline, Five Prime Restructures, Gilead-Galapagos Rheumatism Drug Readout

2019-10-10 21:57:31 | South San Francisco biotech to cut another 70 jobs, may sublease space

2019-10-10 16:01:00 | Five Prime Announces Restructuring

2019-10-02 07:30:00 | Looking for 1,600% Returns? Biotech Has No Shortage of Analyst Optimism

2019-09-30 03:01:00 | Five Prime Therapeutics Presents Updated Data From the Phase 1a/1b Trial of FPA150 at the European Society for Medical Oncology 2019 Congress

2019-09-20 09:59:18 | Peninsula biotech CEO resigns in latest corner office switch

2019-09-19 16:05:00 | Five Prime Therapeutics Announces Management Transition

2019-09-19 12:18:41 | What Kind Of Shareholder Owns Most Five Prime Therapeutics, Inc. NASDAQ:FPRX Stock?

2019-08-22 19:45:00 | Five Prime Therapeutics to Present at Upcoming Healthcare Conference

2019-08-10 00:04:09 | Edited Transcript of FPRX earnings conference call or presentation 7-Aug-19 8:30pm GMT

2019-08-07 18:25:10 | Five Prime Therapeutics FPRX Reports Q2 Loss, Misses Revenue Estimates

2019-08-07 16:05:00 | Five Prime Therapeutics Reports Second Quarter 2019 Results

2019-08-01 15:06:42 | Cancer-fighting Peninsula company postpones $92 million IPO

2019-06-25 11:56:38 | Estimating The Fair Value Of Five Prime Therapeutics, Inc. NASDAQ:FPRX

2019-06-24 16:05:00 | Five Prime Therapeutics Appoints Lori Lyons-Williams to its Board of Directors

2019-06-24 13:28:03 | Is Five Prime Therapeutics Inc FPRX A Good Stock To Buy?

2019-06-18 08:50:12 | Five Prime Therapeutics FPRX Looks Good: Stock Adds 9.2% in Session

2019-06-18 08:04:07 | See what the IHS Markit Score report has to say about Five Prime Therapeutics Inc.

2019-06-11 08:03:05 | See what the IHS Markit Score report has to say about Five Prime Therapeutics Inc.

2019-06-10 08:04:58 | See what the IHS Markit Score report has to say about Five Prime Therapeutics Inc.